ArticleBMC pharmacology & toxicology2021

Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis.

Rasoul Akbari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.